

# CITATION REPORT

List of articles citing

Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotyp

DOI: 10.1016/j.ijmm.2014.02.009

International Journal of Medical Microbiology, 2014, 304, 464-75.

**Source:** <https://exaly.com/paper-pdf/59462959/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
104	.		
103	Blastocystis is associated with decrease of fecal microbiota protective bacteria: comparative analysis between patients with irritable bowel syndrome and control subjects. <b>2014</b> , 9, e111868		98
102	Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. <b>2014</b> , 5, 213-27		120
101	Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. <b>2014</b> , 2014, 567929		44
100	Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. <b>2015</b> , 21, 1219-28		119
99	Gut microbiota as potential orchestrators of irritable bowel syndrome. <b>2015</b> , 9, 318-31		86
98	Levan Enhances Associated Growth of Bacteroides, Escherichia, Streptococcus and Faecalibacterium in Fecal Microbiota. <b>2015</b> , 10, e0144042		38
97	Multilevel regularized regression for simultaneous taxa selection and network construction with metagenomic count data. <b>2015</b> , 31, 1067-74		13
96	Mucin glycan foraging in the human gut microbiome. <b>2015</b> , 6, 81		404
95	Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. <b>2015</b> , 9, 899-906		50
94	Campylobacter jejuni increases flagellar expression and adhesion of noninvasive Escherichia coli: effects on enterocytic Toll-like receptor 4 and CXCL-8 expression. <b>2015</b> , 83, 4571-81		25
93	Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. <b>2015</b> , 81, 7582-92		66
92	Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer. <b>2016</b> , 22, 28-41		73
91	Macrophages Versus Escherichia coli: A Decisive Fight in Crohn's Disease. <b>2016</b> , 22, 2943-2955		4
90	The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. <b>2016</b> , 6, 39399		55
89	Composition and function of the pediatric colonic mucosal microbiome in untreated patients with ulcerative colitis. <b>2016</b> , 7, 384-96		65
88	IBS and IBD - separate entities or on a spectrum?. <b>2016</b> , 13, 613-21		81

87	The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. <b>2016</b> , 51, 1407-1415	116
86	Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases. <b>2016</b> , 62, 208-19	34
85	The Human Microbiome in Health and Disease. <b>2016</b> , 57-76	4
84	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. <b>2016</b> , 9, 199-212	44
83	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. <b>2016</b> , 26, 175-97	32
82	Similar Depletion of Protective <i>Faecalibacterium prausnitzii</i> in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. <b>2016</b> , 10, 1067-75	98
81	<i>Escherichia coli</i> : an old friend with new tidings. <b>2016</b> , 40, 437-463	132
80	Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?. <b>2017</b> , 66, 362-381	37
79	Parasitic Protozoa and Interactions with the Host Intestinal Microbiota. <b>2017</b> , 85,	54
78	<i>Faecalibacterium prausnitzii</i> : from microbiology to diagnostics and prognostics. <b>2017</b> , 11, 841-852	240
77	The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. <b>2017</b> , 46, 481-492	27
76	Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, clinical application, adverse reactions, and outlook. <b>2017</b> , 32, 1804-1812	14
75	Microbiome, inflammation, epigenetic alterations, and mental diseases. <b>2017</b> , 174, 651-660	102
74	Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention. <b>2017</b> , 8, 1674	65
73	New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease. <b>2017</b> , 2017, 8201672	47
72	Deciphering the trophic interaction between <i>Akkermansia muciniphila</i> and the butyrogenic gut commensal <i>Anaerostipes caccae</i> using a metatranscriptomic approach. <b>2018</b> , 111, 859-873	54
71	Comparative genomics reveals new single-nucleotide polymorphisms that can assist in identification of adherent-invasive <i>Escherichia coli</i> . <b>2018</b> , 8, 2695	23
70	Adherent-invasive in inflammatory bowel disease. <b>2018</b> , 67, 574-587	204

69	Recipe for IBD: can we use food to control inflammatory bowel disease?. <b>2018</b> , 40, 145-156	17
68	Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. <b>2018</b> , 19,	80
67	The gut microbiome is required for full protection against acute arsenic toxicity in mouse models. <b>2018</b> , 9, 5424	87
66	Alterations in the Abundance and Co-occurrence of and in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. <b>2018</b> , 8, 281	90
65	Etiopathogenesis of Inflammatory Bowel Diseases. <b>2018</b> , 04,	1
64	in the Human Gastrointestinal Tract: When, Where, and How?. <b>2018</b> , 6,	165
63	Interaction between gut microbiota and ethnomedicine constituents. <b>2019</b> , 36, 788-809	41
62	Altered fecal bacterial composition correlates with disease activity in inflammatory bowel disease and the extent of IL8 induction. <b>2019</b> , 67, 41-50	17
61	Gut microbiota imbalances in Tunisian participants with type 1 and type 2 diabetes mellitus. <b>2019</b> , 39,	18
60	Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?. <b>2019</b> , 17, 2634-2643	41
59	Dietary CNCM I-1079 Positively Affects Performance and Intestinal Ecosystem in Broilers during a Infection. <b>2019</b> , 7,	10
58	Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine. <b>2019</b> , 17, 419	20
57	Isolated colonic Crohn's disease is associated with a reduced response to exclusive enteral nutrition compared to ileal or ileocolonic disease. <b>2019</b> , 38, 1629-1635	5
56	Bacterial imbalance and gut pathologies: Association and contribution of E. coli in inflammatory bowel disease. <b>2019</b> , 56, 1-17	18
55	Development of an Index Score for Intestinal Inflammation-Associated Dysbiosis Using Real-World Stool Test Results. <b>2020</b> , 65, 1111-1124	4
54	The microbiome can predict mucosal healing in small intestine in patients with Crohn's disease. <b>2020</b> , 55, 1138-1149	6
53	Alterations in the diversity and composition of gut microbiota in weaned piglets infected with Balantioides coli. <b>2020</b> , 288, 109298	9
52	Barrier Protection and Recovery Effects of Gut Commensal Bacteria on Differentiated Intestinal Epithelial Cells In Vitro. <b>2020</b> , 12,	7

51	A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls. <b>2020</b> , 2, 193-204	2
50	The critical role of Faecalibacterium prausnitzii in human health: An overview. <b>2020</b> , 149, 104344	37
49	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <b>2020</b> , 11, 2168	95
48	Efficacy of HA-196 and R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. <b>2020</b> , 12,	18
47	Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease. <b>2021</b> , 36, 320-328	14
46	A Novel Grape-Derived Prebiotic Selectively Enhances Abundance and Metabolic Activity of Butyrate-Producing Bacteria in Faecal Samples. <b>2021</b> , 12, 639948	1
45	Location is important: differentiation between ileal and colonic Crohn's disease. <b>2021</b> , 18, 544-558	13
44	Faecalibacterium prausnitzii: A Next-Generation Probiotic in Gut Disease Improvement. <b>2021</b> , 2021, 1-10	7
43	Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment. <b>2021</b> , 11, 10016	7
42	[Irritable bowel syndrome: Role of gut microbiota]. <b>2021</b> , 37, 593-600	
41	Heteropolysaccharides from S. cerevisiae show anti-adhesive properties against E. coli associated with Crohn's disease. <b>2021</b> , 271, 118415	2
40	The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review. <b>2021</b> , 141, 111904	0
39	Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epithelial Barrier and Modulates Cytokine Production In Vitro. <b>2021</b> , 13,	2
38	Mucolytic bacteria: prevalence in various pathological diseases. <b>2021</b> , 37, 176	2
37	Epigenetics of Host Human Gut Microbiome Interactions. <b>2022</b> ,	
36	New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population. <b>2020</b> , 15, e0243158	6
35	Investigation of adherent-invasive in patients with Crohn's disease. <b>2018</b> , 32, 11	3
34	IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities. <b>2020</b> , 10,	5

33	Administration of live, but not inactivated, <i>Faecalibacterium prausnitzii</i> has a preventive effect on dextran sodium sulfate-induced colitis in mice. <b>2019</b> , 20, 25-32	4
32	Gut microbial communities modulate efficacy of albendazole-ivermectin against soil-transmitted helminthiases.	
31	Prebiotic Effect of Bread-Making Process in Inflammatory Bowel Disease Microbiome. <b>2021</b> , 12, 716307	0
30	Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification. <b>2020</b> , 11, 64-77	2
29	The role of major virulence factors and pathogenicity of adherent-invasive in patients with Crohn's disease. <b>2020</b> , 15, 279-288	2
28	How to Analyse Microbial Communities?. <b>2020</b> , 15-29	
27	An Update on the Role of Extracellular Vesicles in the Pathogenesis of Necrotizing Enterocolitis and Inflammatory Bowel Diseases. <b>2021</b> , 10,	1
26	RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment. <b>2021</b> , 27, S63-S66	1
25	Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.. <b>2021</b> , 8, 818902	10
24	Time to revisit disease classification in IBD: is the current classification of IBD good enough for optimal clinical management?. <b>2021</b> ,	2
23	Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders.. <b>2022</b> ,	4
22	Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.. <b>2022</b> , 13, 1063	0
21	<i>Escherichia coli</i> Strains in Patients with Inflammatory Bowel Diseases: A Review. <b>2022</b> , 19, 37-46	
20	Image_1.pdf. <b>2018</b> ,	
19	Image_2.pdf. <b>2018</b> ,	
18	Image_3.pdf. <b>2018</b> ,	
17	Table_1.DOCX. <b>2018</b> ,	
16	Table_2.DOCX. <b>2018</b> ,	

15	Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota. 9,	0
14	Location-specific signatures of Crohn's disease at a multi-omics scale. <b>2022</b> , 10,	1
13	Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. 13,	0
12	Ethnicity influences phenotype and clinical outcomes: Comparing a South American with a North American inflammatory bowel disease cohort. <b>2022</b> , 101, e30216	0
11	Quantitative real-time PCR analysis of bacterial biomarkers enable fast and accurate monitoring in inflammatory bowel disease. 10, e14217	0
10	Relationship between mucosa-associated gut microbiota and human diseases. <b>2022</b> , 50, 1225-1236	3
9	Gut microbiota analysis for prediction of clinical relapse in Crohn's disease. <b>2022</b> , 12,	0
8	Application of computational data modeling to a large-scale population cohort assists the discovery of specific nutrients that influence beneficial human gut bacteria <i>Faecalibacterium prausnitzii</i> .	0
7	Prediction of high fecal propionate-to-butyrate ratios using 16S rRNA-based detection of bacterial groups with liquid array diagnostics.	0
6	Clinical Performance Study of a Fecal Bacterial Signature Test for Colorectal Cancer Screening.	0
5	Microorganisms in the Pathogenesis and Management of Crohn's Disease (CD). <b>2022</b> , 255-269	0
4	Definition of a microbial signature as a predictor of endoscopic post-surgical recurrence in patients with Crohn's disease. 3,	0
3	Effect of food additives on key bacterial taxa and the mucosa-associated microbiota in Crohn's disease. The ENIGMA study. <b>2023</b> , 15,	0
2	Fecal Microbiota Composition as a Metagenomic Biomarker of Dietary Intake. <b>2023</b> , 24, 4918	0
1	Application of Computational Data Modeling to a Large-Scale Population Cohort Assists the Discovery of Inositol as a Strain-Specific Substrate for <i>Faecalibacterium prausnitzii</i> . <b>2023</b> , 15, 1311	0